Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology
Tevogen Bio – June 30th, 2022
Tevogen Bio – June 30th, 2022
Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board
Tevogen Bio – June 23rd, 2022
Tevogen Bio – June 23rd, 2022
Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients
Tevogen Bio – June 7th, 2022
Tevogen Bio – June 7th, 2022
Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio
Tevogen Bio – May 3rd, 2022
Tevogen Bio – May 3rd, 2022
Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness
Tevogen Bio – April 5th, 2022
Tevogen Bio – April 5th, 2022